Skip to main content

Table 1 The regression parameters and statistical analysis of the extracellular concentrations-activity curves illustrated in Fig. 2

From: A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model

Strain Emax (95%CI)a Emin (95%CI)b EC50 (95%CI)c C ds R2e
AF293 − 0.79 (− 0.86 ~ − 0.72) lg cfu 0.21 (0.18 ~ 0.24) lg cfu 7.05 mg/L (5.36 ~ 9.27)
36.71 × MIC (27.91 ~ 48.30)
1.86 mg/L
(9.69 × MIC)
0.9813
AF26 − 0.84 (− 0.89 ~ − 0.78) lg cfu 0.20 (0.16 ~ 0.24) lg cfu 2.11 mg/L (1.63 ~ 2.73)
32.93 × MIC (25.39 ~ 42.70)
0.52 mg/L
(8.32 × MIC)
0.9828
  1. acfu decrease (in lg units) at 24 h from the corresponding original cellular conidia, as extrapolated for infinitely high concentrations of voriconazole (note that a larger maximal relative activity corresponds to a more negative value of Emax)
  2. bcfu increase (in lg units) at 24 h from the corresponding original cellular conidia, as extrapolated for infinitely low concentrations of voriconazole
  3. cExposure (in extracellular concentration and multiple of corresponding MIC) causing a reduction halfway between the Emin and Emax values, as obtained from the hill equation by using a slope factor of − 1
  4. dExposure (in extracellular concentration and multiple of corresponding MIC) resulting in no apparent pathogen growth (the number of cfu was identical to that of the original cellular conidia), as determined by graphical interpolation
  5. eR is coefficient of correlation